Orthocell Ltd's (ASX:OCC) Paul Anderson talks Proactive's Andrew Scott through a new US divisional patent they've secured for CelGro® that covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries. Orthocell has already been granted patents for CelGro® in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand with CelGro® dental (recently renamed Striate+) approved for use in the US, Europe and Australia.
Orthocell Ltd secures new US divisional patent for CelGro®
Quick facts: Orthocell Ltd
Price: 0.49 AUD
Market Cap: $92.51 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE